Therapeutic strategies for type 2 diabetes mellitus patients with very high HbA1c: is insulin the only option?
作者信息
Abdul-Ghani Muhammad, DeFronzo Ralph
机构信息
Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
出版信息
Ann Transl Med. 2018 Dec;6(Suppl 2):S95. doi: 10.21037/atm.2018.11.15.
Abstract
摘要
相似文献
1
Therapeutic strategies for type 2 diabetes mellitus patients with very high HbA1c: is insulin the only option?糖化血红蛋白（HbA1c）水平极高的2型糖尿病患者的治疗策略：胰岛素是唯一选择吗？
Ann Transl Med. 2018 Dec;6(Suppl 2):S95. doi: 10.21037/atm.2018.11.15.
2
Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus.将基础胰岛素治疗方案转换为德谷胰岛素对日本1型和2型糖尿病患者生活质量的影响。
J Pharm Health Care Sci. 2015 Sep 30;1:26. doi: 10.1186/s40780-015-0027-2. eCollection 2015.
3
4
Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: An analysis from the OpT2mise randomized trial.与使用基础-餐时胰岛素方案治疗血糖控制不佳的 2 型糖尿病患者接受持续皮下胰岛素输注治疗后血糖控制改善相关的因素：来自 OpT2mise 随机试验的分析。
Diabetes Obes Metab. 2017 Oct;19(10):1490-1494. doi: 10.1111/dom.12960. Epub 2017 Jul 25.
5
Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria.血糖自我监测频率与长期代谢控制有关吗？对来自德国和奥地利191个中心的24500名患者进行的多中心分析。
Exp Clin Endocrinol Diabetes. 2006 Jul;114(7):384-8. doi: 10.1055/s-2006-924152.
6
Patients' empowerment, physicians' perceptions, and achievement of therapeutic goals in patients with type 1 and type 2 diabetes mellitus in Mexico.墨西哥1型和2型糖尿病患者的自我管理、医生认知及治疗目标达成情况
Patient Prefer Adherence. 2016 Jul 26;10:1349-57. doi: 10.2147/PPA.S107437. eCollection 2016.
8
9
The role of Toujeo®, insulin glargine U-300, in the treatment of diabetes mellitus.托优乐（Toujeo®），即甘精胰岛素U-300，在糖尿病治疗中的作用。
J Am Assoc Nurse Pract. 2016 Sep;28(9):503-9. doi: 10.1002/2327-6924.12357. Epub 2016 Mar 16.
10
Boswellic extracts and 11-keto-ß-boswellic acids prevent type 1 and type 2 diabetes mellitus by suppressing the expression of proinflammatory cytokines.乳香提取物和 11-酮-β-乳香酸通过抑制促炎细胞因子的表达来预防 1 型和 2 型糖尿病。
Phytomedicine. 2019 Oct;63:153002. doi: 10.1016/j.phymed.2019.153002. Epub 2019 Jun 28.
引用本文的文献
1
Determinants of poor glycaemic control and proteinuria in patients with type 2 diabetes: a retrospective analysis of general practice records in Ireland.爱尔兰全科医疗记录的回顾性分析：2 型糖尿病患者血糖控制不佳和蛋白尿的决定因素。
BMC Prim Care. 2024 Jan 10;25(1):22. doi: 10.1186/s12875-023-02252-w.
本文引用的文献
1
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).2018 年美国糖尿病协会（ADA）和欧洲糖尿病研究协会（EASD）的共识报告：2 型糖尿病患者高血糖的管理。
Diabetologia. 2018 Dec;61(12):2461-2498. doi: 10.1007/s00125-018-4729-5.
2
Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES).临床中采用生理评估实现对糖尿病前期的治疗（STOP DIABETES）。
Lancet Diabetes Endocrinol. 2018 Oct;6(10):781-789. doi: 10.1016/S2213-8587(18)30234-1. Epub 2018 Sep 14.
3
A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.一项系统文献综述和网状荟萃分析：比较在既往接受1-2种口服抗糖尿病药物治疗的2型糖尿病患者中，每周一次的司美格鲁肽与其他胰高血糖素样肽-1（GLP-1）受体激动剂的疗效。
Diabetes Ther. 2018 Jun;9(3):1149-1167. doi: 10.1007/s13300-018-0424-2. Epub 2018 Apr 19.
4
Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA: The FREEDOM-1 HBL (High Baseline) Study.新型药物-器械 GLP-1 受体激动剂 ITCA 650 对未经控制的 2 型糖尿病和极高基线 HbA1c 的临床影响：FREEDOM-1 HBL（高基线）研究。
Diabetes Care. 2018 Mar;41(3):613-619. doi: 10.2337/dc17-1519. Epub 2018 Jan 4.
5
Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm.是时候改变2型糖尿病的治疗模式了吗？答案是肯定的！胰高血糖素样肽-1受体激动剂（GLP-1 RAs）应在2型糖尿病治疗方案中取代二甲双胍。
Diabetes Care. 2017 Aug;40(8):1121-1127. doi: 10.2337/dc16-2368.
6
Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes.恩格列净与健康个体及2型糖尿病患者肾脏葡萄糖转运的动力学
Diabetes. 2017 Jul;66(7):1999-2006. doi: 10.2337/db17-0100. Epub 2017 Apr 20.
7
Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c.艾塞那肽联合吡格列酮与基础/餐时胰岛素治疗糖化血红蛋白水平极高的2型糖尿病患者的疗效比较
J Clin Endocrinol Metab. 2017 Jul 1;102(7):2162-2170. doi: 10.1210/jc.2016-3423.
8
Diabetic Retinopathy: A Position Statement by the American Diabetes Association.糖尿病视网膜病变：美国糖尿病协会的立场声明。
Diabetes Care. 2017 Mar;40(3):412-418. doi: 10.2337/dc16-2641.
9
Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.接受胰高血糖素样肽-1 受体激动剂治疗的 2 型糖尿病患者的治疗模式：与每周一次的艾塞那肽和利拉鲁肽相比，度拉糖肽具有更高的依从性和持久性。
Diabetes Obes Metab. 2017 Jul;19(7):953-961. doi: 10.1111/dom.12902. Epub 2017 Mar 16.
10
Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study.在使用磺脲类药物加二甲双胍治疗但血糖控制不佳的2型糖尿病患者中，艾塞那肽联合吡格列酮与基础/餐时胰岛素治疗的对比：卡塔尔研究
Diabetes Care. 2017 Mar;40(3):325-331. doi: 10.2337/dc16-1738. Epub 2017 Jan 17.
Zotero 插件